ALACHUA, Fla.--(BUSINESS WIRE)--

AxoGen, Inc. (AXGN), a leading regenerative medicine company focused on the development and commercialization of products and technologies for peripheral nerve reconstruction and regeneration, today announced approval by the Rizzoli Orthopaedic Institute of its first commercial shipment of Avance Nerve Graft to MD for Life, its new distribution partner in Italy. Avance Nerve Graft is a processed nerve allograft for bridging nerve discontinuities (gaps created when nerves are severed). By eliminating a second surgery to harvest the patients own nerve tissue for use in the repair, Avance Nerve Graft offers an alternative to traditional autograft nerve repair procedures.

The Rizzoli Orthopaedic Institute is Italys largest tissue bank and handles review and approval of all donors of AxoGen processed nerve allograft tissue to assure quality.

"Our ongoing partnership with the prestigious Rizzoli Orthopaedic Institute underscores the quality of AxoGens tissue processing and confirms the growing demand for Avance Nerve Graft in markets outside of the United States," said Karen Zaderej, AxoGen's Chief Executive Officer. "AxoGen is committed to providing innovative technologies of the highest standards to surgeons worldwide for the treatment and reconstruction of injured peripheral nerves.

To date, thousands of patients who have suffered traumatic injuries have been surgically implanted with AxoGens products. In addition to Avance Nerve Graft, the Companys portfolio of products and technologies include AxoGuard Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and AxoGuard Nerve Protector, a bioscaffold used to reinforce a coaptation site, wrap a partially severed nerve or isolate and protect nerve tissue.

About AxoGen, Inc.

AxoGen (AXGN) is a leading regenerative medicine company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body and their damage can result in the loss of function and feeling. In order to improve surgical reconstruction and regeneration of peripheral nerves, AxoGen has developed and licensed patented and patent-pending technologies, which are used in its portfolio of products. This portfolio includes Avance Nerve Graft, a commercially available allograft nerve for bridging nerve discontinuities (a gap created when the nerve is severed) of 5mm to 70mm in length. Avance Nerve Graft is sterilized and processed using a patented cleaning process that preserves the inherent and relevant structural characteristics of the tissue, allowing regenerating axons to grow through the scaffold to the motor or sensory organ.

AxoGens portfolio also includes AxoGuard Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and AxoGuard Nerve Protector, a bioscaffold used to reinforce a coaptation site, wrap a partially severed nerve or isolate and protect nerve tissue.

AxoGen is bringing the science of nerve repair to life with thousands of surgical implants of AxoGen products performed in hospitals and surgery centers across the United States, including military hospitals serving U.S. service men and women.

AxoGen is the parent of its wholly owned operating subsidiary, AxoGen Corporation. AxoGens principal executive office and operations are located in Alachua, FL.

Excerpt from:
AxoGen, Inc. Makes First Commercial Shipment of Avance® Nerve Graft to Distributor in Italy

Comments are closed.